These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 2307172

  • 1. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.
    Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, Wynchauk S, Manciet G, Lefort G.
    Eur J Nucl Med; 1990; 16(1):35-8. PubMed ID: 2307172
    [Abstract] [Full Text] [Related]

  • 2. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
    Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK.
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH.
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [Abstract] [Full Text] [Related]

  • 5. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R.
    Rev Esp Med Nucl; 2007 Jan; 26(3):138-45. PubMed ID: 17524307
    [Abstract] [Full Text] [Related]

  • 8. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P.
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [Abstract] [Full Text] [Related]

  • 9. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
    Moser E, Fritsch S, Braun S.
    Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
    Grünwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ.
    J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
    [Abstract] [Full Text] [Related]

  • 14. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC, Sundram FX, Sin AE.
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [Abstract] [Full Text] [Related]

  • 15. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.
    Lee HJ, Rha SY, Jo YS, Kim SM, Ku BJ, Shong M, Kim YK, Ro HK.
    Am J Clin Oncol; 2007 Feb; 30(1):63-8. PubMed ID: 17278897
    [Abstract] [Full Text] [Related]

  • 16. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
    Ma C, Xie J, Kuang A.
    J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
    [Abstract] [Full Text] [Related]

  • 17. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
    Roelants V, Nayer PD, Bouckaert A, Beckers C.
    Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
    [Abstract] [Full Text] [Related]

  • 18. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
    Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, Monson JP, Besser GM.
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
    [Abstract] [Full Text] [Related]

  • 19. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
    Gómez Camarero P, Martínez Brocca MA, Rodríguez Rodríguez JR, Navarro González E, Tirado Hospital JL, González Duarte D, Vázquez Albertino R, Astorga Jimenez R.
    Rev Esp Med Nucl; 2003 Oct; 22(5):295-305. PubMed ID: 14534005
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.